But well-established ICIs, including blockades targeting CTLA-4 and PD-1/PDL-1, only apply to a subset of cancer patients due to heterogeneous gene expressions and microenvironment across various cancer types (6), and as such novel therapeutic targets need to be considered (7, 8). Here, CTLA4 is linked to cancer.